COMPARATIVE EVALUATION OF LEVETIRACETAM AND BRIVARACETAM IN THE MANAGEMENT OF FOCAL EPILEPSY: A PROSPECTIVE OBSERVATIONAL STUDY
DOI:
https://doi.org/10.22159/ajpcr.2026v19i4.57427Keywords:
Focal Epilepsy, Levetiracetam, Brivaracetam, Quality of Life, Antiepileptic DrugsAbstract
Objective: Focal epilepsy accounts for the majority of epilepsy cases in the global scenario and is often intractable to therapy because of variability in etiology and drug resistance. Levetiracetam (LEV) and its more recently developed analogue brivaracetam (BRV), are widely prescribed antiepileptic drugs acting through synaptic vesicle protein 2A. The present study compares the efficacy, tolerability, and impact on the quality of life of both LEV and BRV in Indian patients with focal epilepsy.
Methods: A prospective comparative observational study was done at KIMS Hospitals, Rajahmundry for 6 months. Sixty adult patients were enrolled using purposive sampling and divided into two groups: LEV-Group A and BRV-Group B. Seizure frequency and health-related quality of life by World Health Organization Quality of Life-BREF were assessed at baseline, 3 months, and 6 months. The statistical tools used included paired and independent t-tests. Results with p<0.05 were considered significant.
Results: Both LEV and BRV were associated with a significant reduction in seizure frequency, with p<0.001. BRV was associated with a numerically greater mean reduction of 2.56 versus 2.17, though this did not reach statistical significance. Quality-of-life improvement was noted in both groups, though higher gains were realized in the BRV group in various areas: Physical and psychological. In both, the reported adverse effects were of a mild nature, though behavioral disturbances were more frequent with LEV.
Conclusion: LEV and BRV are equal in efficacy with regard to seizure control, but BRV shows better tolerability and a slightly greater improvement in quality of life, supporting its role as a preferred alternative for patients who are intolerant to LEV.
Downloads
References
1. Zhang L, Li S, Li H, Zou X. Levetiracetam vs. Brivaracetam for adults with refractory focal seizures: a meta-analysis and indirect comparison. Seizure. 2016 Jul 1;39:28-33. doi: 10.1016/j.seizure.2016.05.004, PMID 27236448
2. Subramonian A, Farrah K. Brivaracetam versus Levetiracetam for Epilepsy: A Review of Comparative Clinical Safety [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec 1. PMID: 33555772.
3. Hsu MY, Hu SW, Fan HC. Comparative analysis of brivaracetam and levetiracetam in epilepsy treatment. Tungs Med J. 2025 Jan 1;19(1):27-31. doi: 10.4103/etmj.etmj-d-24-00027
4. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L. ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512-21. doi: 10.1111/epi.13709, PMID 28276062
5. Zhu LN, Chen D, Xu D, Tan G, Wang HJ, Liu L. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison. Seizure. 2017 Oct 1;51:121-32. doi: 10.1016/j.seizure.2017.07.017, PMID 28854405
6. Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis. Neurology. 2016 Apr 5;86(14):1344-52. doi: 10.1212/wnl.0000000000002545, PMID 26944275
7. Sivadasan S, Raj FB, John K, Murugan S, Sam SS, Elumalai SK. Effectiveness and safety of Brivaracetam in comparison with levetiracetam in seizures. Acta Epileptol. 2025 Dec;7(1):47. doi: 10.1186/s42494-025-00229-z, PMID 41039508
8. Pandya R, Sundaram PK, Baghel SS. Comparison of effectiveness of brivaracetam and levetiracetam for prophylaxis of early post-traumatic seizures: A prospective comparative interventional study. Asian J Neurosurg. 2024 Dec;19(4):728-34. doi: 10.1055/s-0044-1790516, PMID 39606308
9. Thieffry S, Klein P, Baulac M, Plumb J, Pelgrims B, Steeves S. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs. Epilepsia. 2020 Apr;61(4):595-609. doi: 10.1111/epi.16476, PMID 32201951
10. Liguori C, Manfredi N, Renna R, Izzi F, Pagliuca M, Pagliuca F. Comparison of the effectiveness and tolerability of perampanel and Brivaracetam: A real-world, observational, retrospective study. Epileptic Disord. 2020;22(3):309-16. doi: 10.1684/epd.2020.1165, PMID 32540833
11. Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-a monocenter survey. Seizure. 2017 May;48:11-4. doi: 10.1016/j.seizure.2017.03.010, PMID 28364655
12. Vithoba Panchal G, Nath Mishra V. A brief review on efficacy and safety of Brivaracetam in the management of partial onset epilepsy. IP Indian J Neurosci. 2021 Jul 15;7(2):99-105. doi: 10.18231/j.ijn.2021.017
13. Klein P, Schiemann J, Sperling MR, Whitesides J, Liang W, Stalvey T. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015 Dec;56(12):1890-8. doi: 10.1111/epi.13212, PMID 26471380
14. Ranganathan LN, Kulkarni G, Kakkad A, Korukonda K, Chouksey N. First clinical post-approval, observational study to assess clinical safety and effectiveness of Brivaracetam sustained-release formulation in real-life settings of India: BEAM study. Seizure. 2025 Jan 8;125:132-9. doi: 10.1016/j.seizure.2025.01.011, PMID 39837074
15. Maryenko LB, Marienko KM. Levetiracetam is a modern solution to the problem of epilepsy in neuropediatric practice. Int Neurol J. 2022 Mar;18(1);54-62. doi: 10.22141/2224-0713.18.1.2022.930
Published
How to Cite
Issue
Section
Copyright (c) 2026 L.S.D Sireesha K, Himaja Kumari Ponnada, Anusha Vara prada Nakka, Sai Sri Kalam, Sayantika Datta, Sai Shashank Gudla
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.